The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Fresenius Boston-TKC
Boston, Massachusetts, United States
BWH/FH/DCI Outpatient Dialysis Unit
Boston, Massachusetts, United States
Changes in Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET): FDG-PET/CT Dual Scan Score
Time frame: Baseline and 6 months
Changes in High Sensitivity C-Reactive Protein (Hs-CRP) Level
Time frame: Baseline and 6 months
Changes in Interleukin-6 (IL-6) Level
Time frame: Baseline and 6 months
Albumin Levels
Time frame: Baseline and 6 months
Erythropoiesis Stimulating Agent (ESA) Dose Requirement
Time frame: Baseline and 6 months
Hemoglobin Level
Time frame: Baseline and 6 months
Rate of Cardiovascular Events
Time frame: Baseline and 6 months
Hemodialysis Access Stenosis/Thrombosis
Time frame: Baseline and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Fresenius Framingham (#1109)
Framingham, Massachusetts, United States
Fresenius Marlborough (#3448)
Marlborough, Massachusetts, United States
Fresenius Medford Dialysis (#1246)
Medford, Massachusetts, United States
Fresenius Quincy (#1610)
Quincy, Massachusetts, United States
Fresenius Roxbury (#1630)
Roxbury, Massachusetts, United States
DCI Dialysis Unit-Somerville
Somerville, Massachusetts, United States
Fresenius QCDC-Weymouth (#9144)
Weymouth, Massachusetts, United States